作者cozzi (冰裂叠影)
看板Bioindustry
标题[新闻] 醣质定序
时间Wed Oct 13 23:26:07 2004
学生时期觉得醣类研究相当复杂，未能建立什麽概念，今天看到这新闻还真觉得
美妙。这影响生技产业重要因素不仅在於醣类本身有医疗功效外，更能大幅改善
生技学名药的醣基化的不确定性。
出处：
http://biz.yahoo.com/prnews/041012/netu044_1.html
标题：Momenta Pharmaceuticals' Technology Featured in Nature Reviews
内容：
请参照网址内容
延伸阅读：
1.About Momenta
Momenta Pharmaceuticals, Inc. is a biotechnology company specializing in
the sequencing and engineering of complex sugars for the development of
improved versions of existing drugs, the development of novel drugs and
the discovery of new biological processes. Momenta is also utilizing its
ability to sequence sugars to create technology-enabled generic products.
The Company's most advanced product candidate is M-Enoxaparin, a technology-
enabled generic version of LovenoxR. Based on its understanding of complex
sugars, Momenta has created a diversified pipeline of novel discovery and
development candidates. Momenta was founded in 2001 and is headquartered
in Cambridge, MA.
2.给生物科技加点「醣」
http://www.sciam.com.tw/circus/circusshow.asp?FDocNo=154&DocNo=245&CL=21
--
※ 发信站: 批踢踢实业坊(ptt.cc)
◆ From: 210.244.69.64